Greg Kricorian

2.0k total citations · 2 hit papers
34 papers, 1.4k citations indexed

About

Greg Kricorian is a scholar working on Dermatology, Immunology and Hematology. According to data from OpenAlex, Greg Kricorian has authored 34 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Dermatology, 16 papers in Immunology and 10 papers in Hematology. Recurrent topics in Greg Kricorian's work include Psoriasis: Treatment and Pathogenesis (14 papers), Dermatology and Skin Diseases (13 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Greg Kricorian is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (14 papers), Dermatology and Skin Diseases (13 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Greg Kricorian collaborates with scholars based in United States, Canada and United Kingdom. Greg Kricorian's co-authors include Paul Klekotka, Kim Papp, Richard G. Langley, Ajay Nirula, Leon Kircik, Kenneth G. Gross, Alice B. Gottlieb, Elizabeth H. Thompson, C. Paul and Kristian Reich and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

Greg Kricorian

33 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

2016 376 citations Kim Papp, Kristian Reich et al. British Journal of Dermatology profile →
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

2024 39 citations Michael Croft, Ehsanollah Esfandiari et al. American Journal of Clinical Dermatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Greg Kricorian	946	767	227	194	192	34	1.4k
Rosita Saraceno	1.1k 1.2×	906 1.2×	207 0.9×	310 1.6×	228 1.2×	76	1.8k
Marianne Notter	1.3k 1.4×	732 1.0×	161 0.7×	342 1.8×	266 1.4×	9	1.6k
Jensen Yeung	779 0.8×	991 1.3×	183 0.8×	291 1.5×	230 1.2×	145	1.7k
Abby S. Van Voorhees	1.1k 1.2×	884 1.2×	131 0.6×	364 1.9×	309 1.6×	13	1.8k
Bruce Miller	507 0.5×	540 0.7×	156 0.7×	188 1.0×	124 0.6×	32	1.1k
Norman Wasel	1.6k 1.7×	949 1.2×	171 0.8×	388 2.0×	303 1.6×	20	2.0k
Yukari Okubo	1.3k 1.4×	1.1k 1.5×	210 0.9×	365 1.9×	354 1.8×	138	2.0k
Annamaria Mazzotta	756 0.8×	448 0.6×	84 0.4×	193 1.0×	129 0.7×	29	901
Antonella Di Cesare	1.2k 1.2×	733 1.0×	190 0.8×	209 1.1×	226 1.2×	38	1.6k
Claudio Bonifati	838 0.9×	433 0.6×	82 0.4×	346 1.8×	159 0.8×	53	1.3k

Countries citing papers authored by Greg Kricorian

Since Specialization

Citations

This map shows the geographic impact of Greg Kricorian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Kricorian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Kricorian more than expected).

Fields of papers citing papers by Greg Kricorian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Kricorian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Kricorian. The network helps show where Greg Kricorian may publish in the future.

Co-authorship network of co-authors of Greg Kricorian

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Kricorian. A scholar is included among the top collaborators of Greg Kricorian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Kricorian. Greg Kricorian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guttman‐Yassky, Emma, Eric L. Simpson, Robert Bissonnette, et al.. (2025). ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis. Immunotherapy. 17(2). 83–94. 5 indexed citations

Croft, Michael, Ehsanollah Esfandiari, Hailing Hsu, et al.. (2024). OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target. American Journal of Clinical Dermatology. 25(3). 447–461. 39 indexed citations breakdown →

Curtis, Jeffrey R., Paul Emery, Greg Kricorian, et al.. (2023). Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis. The Journal of Rheumatology. 50(9). 1114–1120.

Pappas, Dimitrios A., Ying Shan, Greg Kricorian, et al.. (2020). Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. ACR Open Rheumatology. 2(10). 588–594. 4 indexed citations

Pappas, Dimitrios A., Heather J. Litman, Greg Kricorian, et al.. (2020). Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. Rheumatology International. 41(2). 381–390. 5 indexed citations

Cohen, Stanley, Bradley S. Stolshek, Hao Zhang, et al.. (2019). Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial. Rheumatology and Therapy. 6(2). 245–254. 13 indexed citations

Strober, Bruce, Kim Papp, Mark Lebwohl, et al.. (2016). Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology. 75(1). 77–82.e7. 93 indexed citations

Nirula, Ajay, Jon Nilsen, Paul Klekotka, et al.. (2016). Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases. Lara D. Veeken. 55(suppl 2). ii43–ii55. 42 indexed citations

Paller, Amy S., Elaine C. Siegfried, David M. Pariser, et al.. (2016). Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. Journal of the American Academy of Dermatology. 74(2). 280–287.e3. 73 indexed citations

10.

Papp, Kim, Alan Menter, Bruce Strober, et al.. (2014). Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology. 72(3). 436–439.e1. 36 indexed citations

11.

Papp, Kim, Craig L. Leonardi, Alan Menter, et al.. (2014). Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. Journal of the American Academy of Dermatology. 71(6). 1183–1190.e3. 93 indexed citations

12.

Lebwohl, Mark, Leon Kircik, Kristina Callis Duffin, et al.. (2013). A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 69(3). 385–392. 21 indexed citations

13.

Gottlieb, Alice B., Richard G. Langley, Bruce Strober, et al.. (2012). A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. British Journal of Dermatology. 167(3). 649–657. 99 indexed citations

14.

Paller, Amy S., Elaine C. Siegfried, Lawrence F. Eichenfield, et al.. (2010). Long-term etanercept in pediatric patients with plaque psoriasis. Journal of the American Academy of Dermatology. 63(5). 762–768. 72 indexed citations

15.

Gattu, Shilpa, et al.. (2009). Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. Journal of the American Academy of Dermatology. 61(5). 793–798. 18 indexed citations

16.

Wu, Jashin J., et al.. (2007). Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea. Clinical and Experimental Dermatology. 32(6). 693–695. 30 indexed citations

17.

Gross, Kenneth G., Leon Kircik, & Greg Kricorian. (2007). 5% 5-Fluorouracil Cream for the Treatment of Small Superficial Basal Cell Carcinoma: Efficacy, Tolerability, Cosmetic Outcome, and Patient Satisfaction. Dermatologic Surgery. 33(4). 433–440. 104 indexed citations

18.

Ondo, William G., Kapil D. Sethi, & Greg Kricorian. (2007). Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms. Clinical Neuropharmacology. 30(5). 295–300. 30 indexed citations

19.

Iyer, Shilesh, et al.. (2004). Full face laser resurfacing: Therapy and prophylaxis for actinic keratoses and non‐melanoma skin cancer. Lasers in Surgery and Medicine. 34(2). 114–119. 55 indexed citations

20.

Iyer, Shilesh, et al.. (2004). Treatment of Basal Cell Carcinoma with the Pulsed Carbon Dioxide Laser: A Retrospective Analysis. Dermatologic Surgery. 30(9). 1214–1218. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact